Dakota Wealth Management raised its stake in Regeneron Pharmaceuticals by 122.0% in Q4, holding 3,126 shares worth $2.41 million. Analysts rate REGN as a "Moderate Buy," with a target price of $802.27, despite some insider sell-offs.

NodeGuardian

2026-04-14 10:38:24

Abstract generation in progress

Dakota Wealth Management significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 122.0% in the fourth quarter, bringing its total holdings to 3,126 shares valued at $2.41 million. This increase is part of a broader trend of institutional investment, though some insiders have recently sold shares. Analysts currently have a “Moderate Buy” rating for REGN, with a consensus target price of $802.27.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
WCTCTradingChallengeShare8MUSDT
673.09K Popularity
#
GateMarchTransparencyReport
32.7K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
768K Popularity
#
USBlocksStraitofHormuz
740.91K Popularity
#
Gate13thAnniversary
186K Popularity

Sitemap

Dakota Wealth Management Has $2.41 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Trending Topics

WCTCTradingChallengeShare8MUSDT

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

Gate13thAnniversary

Pin